User:Jonas Cicenas

Date and place of birth: December 17, 1974; Klaipeda, Lithuania.

Citizenship: Lithuania, EU.

Present residence: Bern, Switzerland

Education:

1982-1993:Klaipeda School No. 19;

1993-1997 and 1997-1999: Faculty of Natural Sciences,Vilnius Pedagogical University (biology);

1997: BSc degree in natural sciences;

1999: MSc degree in natural sciences.

1994-1996 Private College "Lingua et Commercium" (Economics, Marketing, Informatics, German and English).

1999-2000: Dept. Anatomy and Cell Biology, East Carolina University School of Medicine.

2002-2004: University of Basel.

2004: PhD degree in biochemistry.

Bachelor's thesis: „Influence of cytokines on the proliferation and differentiation of bovine blood lymphocytes“.

Master's thesis: „Influence of protein kinases and nucleotide analogues on the differentiation and apoptosis of the HL-60 cell line“.

PhD thesis: „ErbB2 Signaling in Breast Cancer: the role of ErbB, Akt and ShcA phosphorylation“.

Work experience:

1996-1997: Institute of Immunology, Lithuania (undergraduate student);

1997-1999: Institute of Biochemistry, Lithuania (laboratory assistant);

1999-2000: Dept. Anatomy and Cell Biology, East Carolina University School of Medicine, Greenville, NC, USA (PhD student).

2000-2001 GSF Research Center, Munich, Germany (PhD student)

2002-2004: Molekulare Tumorbiologie, Department Forshung, Kantonspital Basel and Stiftung Tumorbank Basel (PhD student)

2005-2007: Division of Clinical Immunology, Departement of Clinical Veterinary Medicine, University of Bern (postdoc).

2008: Evolutionary Biology, Zoological Institute, University of Basel (postdoc)

2009-2010: Unit of Gene Therapy & Stem Cell Biology, Hõpital Jules-Gonin, Lausanne (postdoc)

Since 1.3.2010 Laboratory for Molecular Medicine and Hematology, Department of, Clinical Research, Inselspital Bern (postodc)

Publications

• Cicenas, J.; Küng, W.; Eppenberger, U.; Eppenberger-Castori, S. Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor. Cancers 2010, 2, 153-164.

• Cicenas J. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers. 2008 Jan-Mar;23(1):1-9. Review. PubMed PMID: 18409144.

• Cicenas J. The potential role of the EGFR/ERBB2 heterodimer in breast cancer. Expert Opinion Ther Patents Volume: 17 Issue: 6 Pages: 607-616 Published: JUN 2007

• Weissenstein U, Schneider MJ, Pawlak M, Cicenas J, Eppenberger-Castori S,Oroszlan P, Ehret S, Geurts-Moespot A, Sweep FC, Eppenberger U. Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts. Proteomics. 2006 Mar;6(5):1427-36. PubMed PMID: 16440370.

• Cicenas J, Urban P, Küng W, Vuaroqueaux V, Labuhn M, Wight E, Eppenberger U, Eppenberger-Castori S. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur J Cancer. 2006 Mar;42(5):636-45. Epub 2006 Jan 18. PubMed PMID: 16414259.

• Cicenas J, Urban P, Vuaroqueaux V, Labuhn M, Küng W, Wight E, Mayhew M, Eppenberger U, Eppenberger-Castori S. Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res. 2005;7(4):R394-401. Epub 2005 Mar 24. PubMed PMID: 15987444; PubMed Central PMCID: PMC1175052.